Background: Systemic sclerosis is an immune-mediated rheumatic disease characterized by vascular abnormalities, tissue fibrosis and autoimmune phenomena. Summary: Renal disease occurring in patients with systemic sclerosis may have a variable clinicopathological picture. The most specific renal condition associated with systemic sclerosis is scleroderma renal crisis, characterized by acute onset of renal failure and severe hypertension. Although the management of scleroderma renal crisis was revolutionized by the introduction of angiotensin-converting enzyme inhibitors, there is still a significant proportion of patients with poor outcomes. Therefore, research on establishing disease markers (clinical, ultrasonographical and serological) and clear diagnostic criteria, which could limit the risk of developing scleroderma renal crisis and facilitate diagnosis of this complication, is ongoing. Other forms of renal involvement in systemic sclerosis include vasculitis, an isolated reduced glomerular filtration rate in systemic sclerosis, antiphospholipid-associated nephropathy, high intrarenal arterial stiffness and proteinuria. Key Messages: Scleroderma renal crisis is the most specific and life-threatening renal presentation of systemic sclerosis, albeit with declining prevalence. In patients with scleroderma renal crisis, it is mandatory to control blood pressure early with increasing doses of angiotensin-converting enzyme inhibitors, along with other antihypertensive drugs if necessary. There is a strong association between renal involvement and patients’ outcomes in systemic sclerosis; consequently, it becomes mandatory to find markers that may be used to identify patients with an especially high risk of scleroderma renal crisis.

Systemic sclerosis (SSc) is a chronic multisystem disease characterized by thickening of the skin and fibrosis of various internal organs [1, 2]. Although the exact pathogenesis of SSc still remains incompletely understood, vasculopathy and dysregulation of the immune system are considered to play a significant role [3].

In SSc one of the most significant, acute consequences of vasospasm and arterial damage is renal involvement. In contrast to pulmonary arterial hypertension, which is characterized by slowly progressive vasculopathy, the vascular changes in renal scleroderma usually develop rapidly due to higher values of systemic blood pressure in comparison to pulmonary pressure [4]. The renal involvement in SSc may remain subclinical until the late stages [5]. Autopsy studies reveal occult renal pathology in 60–80% of SSc patients [6]. Cannon et al. [7] found that up to 50% of asymptomatic patients have clinical markers indicative of renal dysfunction, such as proteinuria, an increased creatinine concentration, or hypertension. Various studies suggest a strong association between renal involvement and worse patient outcomes in SSc [3, 8]. In addition, a multinational SSc inception cohort study found renal crisis to be one of the predictors of early mortality in SSc patients [9].

The most studied form of renal involvement, associated with the most dramatic clinical course, is scleroderma renal crisis (SRC). The other forms of renal involvement include antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, an isolated reduced glomerular filtration rate (GFR) in SSc, antiphospholipid (aPL)-associated nephropathy, high intrarenal arterial stiffness and proteinuria (Fig. 1).

Fig. 1.

The spectrum of kidney involvement in systemic sclerosis. c-ANCA, diffuse cytoplasmic staining; anti-PR3, anti-proteinase 3 antibodies; p-ANCA, perinuclear pattern; anti-MPO, anti-myeloperoxidase antibodies.

Fig. 1.

The spectrum of kidney involvement in systemic sclerosis. c-ANCA, diffuse cytoplasmic staining; anti-PR3, anti-proteinase 3 antibodies; p-ANCA, perinuclear pattern; anti-MPO, anti-myeloperoxidase antibodies.

Close modal

The most specific form of renal involvement in SSc is SRC, characterized by acute onset of renal failure and severe hypertension. On presentation, 90% of patients with SRC consistently have blood pressure levels exceeding 150/90 mm Hg and decreased renal function (≥30% reduction in estimated GFR [eGFR]). SRC occurs in 10–15% of patients with diffuse cutaneous SSc (dcSSc) and only rarely (1–2%) in limited cutaneous SSc (lcSSc) [10, 11]. SRC was a predominant cause of death in previous decades [12, 13]; however, in recent years, declining trends have been observed [14]. An analysis of 637 patients with dcSSc with a disease duration <4 years from the European League against Rheumatism Scleroderma Trials and Research (EUSTAR) cohort has shown the prevalence of SRC at an estimated 2.4% [15, 16].

Pathogenesis of SRC

The exact pathogenesis of SRC is still under investigation, but genetic and environmental factors are likely involved. The primary pathogenic process is thought to be injury to endothelial cells resulting in intimal thickening and proliferation of the renal intralobular and arcuate arteries. SRC appears histologically as “onionskin lesions” of the renal interlobular arteries [17]. Antiendothelial cell antibodies, which are capable of inducing endothelial cell apoptosis, have been detected in up to 85% of SSc patients [18]. In addition to structural changes, episodic vasospasm, named “renal Raynaud’s phenomenon,” contributes to renal hypoperfusion, increased renin release and juxtaglomerular hyperplasia. Hyperreninemia causes vasoconstriction and renal ischemia, which contributes to accelerated hypertension [19-21]. Endothelin-1, a peptide that plays a role in blood vessel constriction, and its receptor ET-B are overexpressed in patients with SRC [22].

Alterations in cellular and humoral immunity may both play a role in SRC pathogenesis [23-25]. SSc has been associated with activation of type 2 helper T lymphocytes, cytokine production and excess collagen accumulation, all of which participate in the development of vasculopathy [26]. The potential pathogenic role of specific autoantibodies is implied by the association between their presence and the development of SRC [27, 28]. Furthermore, the complement degradation product C4d, which is regarded as an immunologic marker of antibody-mediated rejection of renal allografts, was detected in native renal biopsies from a subset of SRC patients [29].

There is a strong relationship between SRC development and specific MHC classes, in particular HLA (human leukocyte antigen)-DRB1*0407 and HLA-DRB1*1304. Additionally, gene screening studies showed an association of SRC with genes in the complement region. Polymorphism in the endothelin ligand receptor axis, but not in the angiotensin-converting enzyme (ACE) axis, has also been associated with an increased risk of SRC [30].

CD147, also known as extracellular matrix metalloproteinase inducer, is a glycosylated membrane protein which belongs to the immunoglobulin superfamily. Yanaba et al. [31] found that an increased concentration of serum soluble CD147 was associated with the presence of SRC. Therefore, CD147 may play a role in the development of SRC, and measurement of circulating soluble CD147 may be a useful biomarker for SRC risk stratification.

Clinical Symptoms of SRC

Patients with SRC may present with headaches, hypertensive retinopathy, encephalopathy, seizures, fever and general malaise. Pulmonary edema is also common, resulting from water and salt retention due to overload and oliguria [32, 33].

Laboratory tests of patients with SRC reveal multiple abnormalities. A rapid increase in serum creatinine concentration and/or microangiopathic hemolytic anemia is associated with severe glomerular damage and with intravascular hemolysis [34]. In addition, the renin concentration is also significantly increased [7]. Urinalysis commonly demonstrates mild proteinuria and hematuria with granular casts visible on microscopy [35]. Markers of endothelial cell perturbation have been observed, including a high concentration of soluble adhesion molecules in the blood (VCAM-1, ICAM-1 and E-selectin) [36].

Ninety-nine experts evaluated a broad list of potential diagnostic criteria in order to identify key aspects of SRC [37], the results of the study were used for the development of classification criteria for SRC (Fig. 2). A consensus was reached regarding the following aspects and may be a useful tool that summarizes valid clinical features of SRC, thus directing the diagnosis.

Fig. 2.

Proposed diagnostic criteria for scleroderma renal crisis (SRC). SBD, systolic blood pressure (German: “systolischer Blutdruck”); DBP, diastolic blood pressure; KDIGO, Kidney Disease: Improving Global Outcomes.

Fig. 2.

Proposed diagnostic criteria for scleroderma renal crisis (SRC). SBD, systolic blood pressure (German: “systolischer Blutdruck”); DBP, diastolic blood pressure; KDIGO, Kidney Disease: Improving Global Outcomes.

Close modal

Blood Pressure. (1) Acute rise in blood pressure defined as one or both of the following: systolic blood pressure >140 mm Hg; diastolic blood pressure >90 mm Hg. (2) A rise in systolic blood pressure >30 mm Hg above normal and/or diastolic blood pressure >20 mm Hg above normal. (3) Blood pressure measurement should be taken twice, separated by at least a 5-min interval. (4) If blood pressure readings are discordant, repeat readings should be obtained until 2 consistent readings are obtained.

Kidney Injury. Acute kidney injury fulfilling Kidney Disease: Improving Global Outcomes (KDIGO) criteria.

Microangiopathic Hemolytic Anemia and Thrombocytopenia. (1) New or worsening anemia not due to other causes. (2) Schistocytes or other red blood cell fragments on blood smear. (3) Thrombocytopenia <100,000/μL, confirmed by manual smear. (4) Laboratory evidence of hemolysis: elevated lactate dehydrogenase, reticulocytosis, and/or low/absent haptoglobin. (5) Negative direct antiglobulin test.

Organ Dysfunction. (1) Hypertensive retinopathy confirmed by an ophthalmologist. (2) Hypertensive encephalopathy. (3) Acute heart failure. (4) Acute pericarditis.

Renal Histopathology. Histopathological findings on kidney biopsy consistent with SRC [37].

The proposed diagnostic criteria for SRC are presented in Figure 2.

Renal biopsy is not recommended in patients with SSc presenting with typical features of SRC, but it plays a key role in cases with atypical presentation or in doubtful cases [38-40]. SSc mostly affects the interlobular arteries, in contrast to hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), which predominantly affect the glomeruli. Malignant hypertension-associated thrombotic microangiopathy may have an appearance identical to that seen in SSc, although this is more often associated with underlying arterionephrosclerosis. Clinical history and serological data help to distinguish these etiologies [41]. Table 1 shows the differential diagnosis of SRC.

Table 1.

Differential diagnosis of scleroderma renal crisis

Differential diagnosis of scleroderma renal crisis
Differential diagnosis of scleroderma renal crisis

Risk Factors for SRC Development

Rapidly progressive skin thickening appears to be the main risk factor for SRC, with most dcSSc patients developing SRC within 7.5 months to 4 years of disease onset [10, 11, 42]. According to Moinzadeh et al. [43], development of proteinuria and/or hypertension, as well as positive anti-RNA polymerase III (anti-RNAP III) antibodies are the strongest risk factors for SRC. Terras et al. [44] and Stochmal et al. [45] showed that the presence of anti-RNAP III antibodies in patients with SSc correlates with renal crisis and severe cutaneous involvement. Although an association between SRC and anti-RNAP III antibodies has already been reported in patients with dcSSc, Takada et al. [46] recently reported a case of anti-RNAP III antibody-associated SRC in a patient with lcSSc.

A number of other risk factors have been identified, for example, anemia [42], recent cardiac events, large joint contractures [47], digital pitting scars, myalgia and myopathy [38]. Shimizu et al. [48] reported a case of SRC complicated by thrombotic microangiopathy in a patient with no other risk factors after infection with influenza B virus. In regard to medications, glucocorticoids have been implicated as a major risk factor when used in doses ≥15 mg per day in the preceding 6 months [49]. It is hypothesized that high doses of corticosteroids can promote endothelial dysfunction and inhibit prostacyclin production, which in turn increase ACE activity [50]. Cyclosporin therapy is another risk factor for SRC development [51].

Treatment of SRC and Preventive Measures

The key to management of SRC is early detection and treatment with ACE inhibitors (ACE-I) [52]. The EULAR recommends ACE-I as first-line treatment, and that patients started on steroids should be carefully monitored for the development of SRC [53]. Studies have shown that if the diagnosis of SRC is delayed or if ACE-I are not used aggressively, irreversible kidney damage and death are more likely to occur [34, 54]. Early detection and aggressive treatment are also crucial to prevent other complications associated with SRC, such as hypertension, retinopathy and pulmonary edema [35]. Unfortunately, the data show that over half of SRC cases have a delay in diagnosis, and thus long-term mortality remains significant [55]. If blood pressure control remains suboptimal at the maximum tolerated doses of ACE-I, other antihypertensive drugs (calcium channel blockers as second-line and diuretics or alpha-blockers as third-line treatment) should be added. Angiotensin II receptor blockers should be used only in patients intolerant to ACE-I [52]. There has also been recent interest in combining ACE-I with endothelin receptor blockers and agents targeting complement component 5 [54]. The target for antihypertensive treatment is to decrease systolic blood pressure by 20 mm Hg and diastolic blood pressure by 10 mm Hg per 24 h to the normal range, avoiding hypotension.

Risk factors for poor outcome in SRC include the following: a serum creatinine concentration >3 mg/dL at presentation, male gender, a delay in initiating antihypertensive treatment, inadequate blood pressure control, congestive heart failure, normotensive SRC, and renal biopsy findings showing (1) arteriolar fibrinoid necrosis, (2) severe glomerular ischemic collapse or (3) severe tubular atrophy and interstitial fibrosis [50].

In terms of preventive measures, regular blood pressure monitoring and seeking early attention when blood pressure suddenly increases [11, 14] are vital. Patients deemed at high risk for SRC may benefit from shorter follow-up intervals with particular focus on subtle changes or abnormalities in proteinuria and eGFR, intensive home blood pressure monitoring (to include 24-h ambulatory blood pressure monitors) and earlier nephrology consultation [56]. Renal function should be assessed regularly via serum creatinine concentration, eGFR and serum renin concentration, as well as via general urine analysis and 24-h proteinuria [57].

There is no evidence at present to support the use of ACE-I prophylactically, although prompt initiation of treatment remains a key point in SRC therapy. New therapeutic options are needed [14, 53].

Plasma exchange, which has been proposed for thrombotic microangiopathy, has not demonstrated efficacy and should not be recommended, with the exception of rare SRC patients who might develop thrombotic microangiopathy associated with anti-ADAMTS-13 antibodies [58]. There are currently no clinical trial data regarding the use of plasma exchange in SRC.

In severe cases of SRC with systemic complement activation and resistant to conventional treatment, eculizumab, the C5 blocker, has recently been proposed as a possible treatment option. Eculizumab is a humanized recombinant monoclonal antibody directed against complement component 5. The drug inhibits the generation of C5a and C5b-9, and thus inhibits lysis and endothelial damage [59]. The rationale for the involvement of the complement system in the pathogenesis of SRC, as well as for the usage of eculizumab, is as follows: an association of hypocomplementemia with SSc and vascular involvement, occurrence of microangiopathic hemolytic anemia in SRC, C5b-9 deposits in capillaries of SSc patients’ skin biopsies and C4d deposits in renal peritubular capillaries of SSc patients with a poor renal outcome [60].

Renal Replacement Therapy and Renal Transplantation

Despite treatment, dialysis is still needed in 23% of SRC patients, and permanent dialysis in 41% of SRC patients [10]. Up to half of the cases requiring renal replacement therapy eventually come off dialysis, although this may be between 6 and 24 months after the initial SRC. Renal transplantation offers superior survival in SSc compared with long-term dialysis [61], although it should be emphasized that renal transplantation is not always possible due to the severe multiorgan involvement. In a cohort of 260 patients with SSc who underwent kidney transplantation, the overall 5-year graft survival rate was 56.7% [62]. In a report of the United Network of Organ Sharing, recurrence of disease after transplantation was 6.7% [58]. Based on the finding that cyclosporine may be responsible for acute renal failure in patients with SSc, calcineurin inhibitors are not recommended as immunosuppressants after kidney transplantation [51]. Data from the Australia and New Zealand Dialysis and Transplant (ANZDATA) registry and the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry confirmed that overall survival of SSc patients receiving renal replacement therapy is worse than that of patients with other causes of end-stage renal disease. However, patients with SSc have a higher rate of dialysis-independent renal function recovery [63, 64].

Antinuclear Antibodies Associated with SRC

Autoimmune serology can be used to identify patients at significant risk of SRC. Anti-RNAP III antibodies and anti-topoisomerase I (anti-Topo I/anti-Scl70) have been associated with an increased risk of developing SRC. The anti-centromere antibodies, typically seen in lcSSc, are considered “protective” against renal crisis [65]. A proportion of 16.7–24% of patients with the anti-RNAPIII antibodies develop SRC [44, 66, 67].

An Italian study [68] showed that patients with anti-RNAP I–III antibodies tend to develop SRC early in the course of the disease, while anti-Topo I-positive patients typically develop SRC later. In that study, 100% of the patients who were anti-RNAP I–III positive developed SRC within 18 months from disease onset, and in almost 30% of the patients, SRC was the presenting symptom of the disease. In the anti-Topo I-positive group, the onset of SRC occurred within 18 months of the disease in only 50% of the cases; 23% of the patients developed SRC between 18 and 48 months, and 27% >48 months after the disease onset. All anti-RNAP I–III-positive patients developed hypertensive renal crisis, while in the anti-Topo I group, 40% were diagnosed with the normotensive type of SRC. Patients with anti-Topo I antibodies tended to have higher creatinine levels and a less favorable outcome.

The available data indicate that detecting SSc-specific antibodies with a prognostic value may lead to a better risk stratification.

Other Biomarkers

Chiba et al. [69] found soluble T-cell immunoglobulin and mucin domain 3 (sTIM3) to be more frequently elevated in patients with a history of SRC. Chighizola et al. [70] identified N-terminal prohormone of brain natriuretic peptide (NT-proBNP) as a potentially useful biomarker for risk stratification of renal outcome in SRC, selectively identifying patients likely to require renal replacement therapy.

Recently, adipokines (cell signaling proteins secreted by adipose tissue) have attracted much attention as a cytokine family contributing to the various pathological processes of SSc. Chemerin, one of the adipokines, appears to be a promising marker of increased risk of impaired renal function in the early stage of SSc [71, 72]. Adipsin was suggested to take part in the pathogenesis of SRC due to an alternative pathway of complement activation [60]. Apelin, the secretion of which is decreased in SSc, was reported to inhibit the fibrotic process in numerous organs including the kidneys [73].

Other adipokines have been associated with organ fibrosis in SSc; however, their link with renal involvement is not fully established and requires further investigation (Fig. 3) [74].

Fig. 3.

Potential biomarkers of scleroderma renal crisis (SRC). (1) Promising marker of increased risk of impaired renal function in the early stage of systemic sclerosis; the role in SRC is not established. (2) Inhibits the -fibrotic process in numerous organs including the kidneys, secretion in systemic sclerosis is decreased; the role in SRC is not established. anti-Topo I, anti-topoisomerase I; anti-RNAP III, anti-RNA polymerase III antibodies; sTIM3, soluble T-cell immunoglobulin and mucin domain 3; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.

Fig. 3.

Potential biomarkers of scleroderma renal crisis (SRC). (1) Promising marker of increased risk of impaired renal function in the early stage of systemic sclerosis; the role in SRC is not established. (2) Inhibits the -fibrotic process in numerous organs including the kidneys, secretion in systemic sclerosis is decreased; the role in SRC is not established. anti-Topo I, anti-topoisomerase I; anti-RNAP III, anti-RNA polymerase III antibodies; sTIM3, soluble T-cell immunoglobulin and mucin domain 3; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.

Close modal

Normotensive SRC

In approximately 10% of patients, SRC occurs in the absence of hypertension (normotensive SRC) [75-77]. Relative hypertension may be present, i.e., a significant increase in blood pressure which still remains within the normal range but is elevated compared to the patient’s baseline values (e.g., 130/85 mm Hg in a young woman whose baseline value is 100/70 mm Hg) [78]. Absence of elevated blood pressure in SRC may delay its diagnosis and treatment, leading to disease progression. Therefore, any change in blood pressure or any kidney dysfunction should lead to close monitoring and additional tests. Normotensive renal crisis diagnosis is particularly challenging and requires confirmation of progressive azotemia and/or microangiopathic hemolytic anemia with thrombocytopenia. To diagnose normotensive renal crisis, an elevated serum creatinine concentration and at least one of the following should be found: proteinuria, hematuria, thrombocytopenia, hemolysis or hypertensive encephalopathy.

Normotensive SRC is associated with worse prognosis, a higher mortality rate and an earlier need for renal replacement therapy (Table 2) [11, 75, 79, 80]. The poor outcome has been, in part, attributed to subclinical renal injury leading to thrombotic microangiopathy in the setting of delayed diagnosis. Normotensive SRC is more common in patients with cardiac involvement. Based on several case reports, it was hypothesized that cardiac involvement may preclude a hypertensive response and worsen prognosis [76]. However, a study comparing 15 normotensive renal crisis patients with 116 hypertensive SRC patients did not show differences in the prevalence of cardiac involvement [75]. Significant differences that may contribute to a worse prognosis in normotensive SRC are more frequent occurrences of severe anemia, thrombocytopenia and pulmonary hemorrhage [75]. In the study by Helfrich et al. [75], 64% of the normotensive patients received prednisone ≥30 mg/day compared with 16% of the hypertensive patients. Conversely, 52% of the hypertensive but only 7% of the normotensive patients received no corticosteroids.

Table 2.

Comparison of hypertensive and normotensive SRC

Comparison of hypertensive and normotensive SRC
Comparison of hypertensive and normotensive SRC

Despite the lack of clinical studies, ACE-I are often used in normotensive SRC patients, but they seem to be less effective in this group of patients than in hypertensive SRC patients [81].

ANCA-Associated Vasculitis and SSc

ANCA are autoantibodies directed against enzymes localized within primary granules of neutrophils and lysosomes in monocytes and are implicated directly in the pathogenesis of small vessel vasculitis [82]. ANCA-associated vasculitis is rare in SSc, found in up to 9% of patients [83]. ANCA-associated vasculitis is a systemic necrotizing vasculitis of unknown etiology, including granulomatosis with polyangiitis (previously Wegener’s granulomatosis), microscopic polyangiitis, renal limited vasculitis, and Churg-Strauss syndrome. Two major patterns of ANCA can be distinguished by indirect immunofluorescence: a diffuse cytoplasmic staining pattern (c-ANCA) mainly associated with anti-proteinase 3 (anti-PR3) antibodies, and a perinuclear pattern (p-ANCA) mainly associated with anti-myeloperoxidase (anti-MPO) antibodies. It has been postulated that scleroderma vasculopathy exacerbates the interaction of ANCA with the endothelium near the vascular pole and neutrophil activation in the glomerulus [53].

Most cases of ANCA-associated vasculitis are described as normotensive renal failure related to anti-MPO crescentic glomerulonephritis [84]. In contrast to classic SRC, the majority of such cases occur in lcSSc rather than dcSSc, and the process has a subacute presentation with progressive renal failure, mild hypertension and proteinuria. ANCA-associated vasculitis, in comparison to SRC, causes renal failure due to mononuclear cell infiltration and vessel wall destruction. These two conditions can only reliably be distinguished by histopathological examination [85]. ANCA-associated vasculitis typically occurs after several years of SSc – compared to SRC, which mainly occurs in the earlier stages of disease [86]. The main differences between SRC and ANCA-associated glomerulonephritis are shown in Table 3. Its diagnosis should be considered in any SSc patient with positive MPO antibodies and renal failure.

Table 3.

Comparison of SRC and ANCA-associated vasculitis

Comparison of SRC and ANCA-associated vasculitis
Comparison of SRC and ANCA-associated vasculitis

Isolated Reduced GFR in SSc

Clinically apparent renal involvement is uncommon in SSc. Many patients with SSc demonstrate less severe complications associated with a decreased GFR. The mechanisms of chronic and slowly progressive renal disease in SSc are still not fully elucidated [87]. Patients with SSc with normal kidney function develop blood vessel abnormalities in the kidneys which are comparable to those seen in other organs. In most patients this damage is subclinical. Autopsy studies reveal occult renal pathology in 60–80% of patients with SSc, and almost all of these cases involve vascular abnormalities. It seems that renal involvement in SSc is primarily characterized by vascular damage and glomerular hypofiltration, which is quite different from patients with diabetic or hypertensive nephropathy, where hyperfiltration and increased glomerular capillary pressure represent the major causes of progressive renal dysfunction [6]. Impaired renal function may be present in SSc despite a normal serum creatinine concentration as serum creatinine may not be elevated until the GFR is <50% of normal [6].

There is an association between renal dysfunction and pulmonary hypertension. Campo et al. [88] recently evaluated 76 consecutive SSc patients with pulmonary arterial hypertension and found that at the time of diagnosis, 45.6% had renal dysfunction (eGFR <60 mL/min/1.73 m2), while only 6.5% of them had had a prior episode of renal crisis. Furthermore, eGFR was a strong predictor of survival in this cohort, with eGFR values <60 mL/min/1.73 m2 associated with a 3-fold increase in mortality. This strong association may be a reflection of pulmonary hypertension and right heart failure contributing to renal dysfunction through fluid retention and neuroendocrine activation.

aPL syndrome is characterized by antibodies directed against either phospholipids or plasma proteins bound to anionic phospholipids [89]. The presence of aPL is correlated with a constellation of clinical features including venous and arterial thrombosis, recurrent fetal loss and thrombocytopenia [90]. The prevalence of aPL in SSc varies up to 41% [91, 92]. Although the role of aPL antibodies in the pathogenesis and long-term outcomes of SSc is still unclear, the presence of aPL seems to be correlated with higher involvement of the skin and visceral organs [93, 94]. Wielosz et al. [95] suggest a relationship between kidney involvement and the presence of aPL antibodies in patients with SSc. Positivity for IgG aCL and IgG a-B2GPI in patients with SSc without secondary aPL syndrome seems to be connected with decreased glomerular filtration [95].

Intrarenal vascular stiffness is measured via the renal vascular resistive index; using this method, a surge in arterial stiffness has been documented in SSc patients [96]. Doppler indices of intrarenal stiffness were previously also utilized as markers for prediction of new digital ulcer occurrence in SSc [97]. Additionally, it has been suggested that renal vascular stiffness parameters are increased in SSc patients with the presence of anti-RNAP III antibodies, which are a known risk factor for SRC development [98]. To date, little has been studied on the significance of the observed increase in intrarenal arterial stiffness in terms of patients’ outcomes in long-term observation. Rosato et al. [99] observed renal function in SSc patients in a well-designed prospective trial with a mean follow-up of 4 years using several organ function assessment measures. In accordance with previous studies [96-99], the authors demonstrated increased intrarenal stiffness parameters in Doppler ultrasonography within the study group. During follow-up, all of the patients, except for 6 individuals in whom SRC occurred, had preserved normal renal function despite increased intrarenal stiffness. An important observation was that no significant differences in renal Doppler and serological parameters were observed between patients with renal complications (in whom SRC occurred) and those without renal complications. Doppler indices of intrarenal stiffness were significantly elevated in patients with digital ulcers. The study concluded that asymptomatic renal vasculopathy was present in SSc patients, but it did not seem to be associated with accelerated deterioration of renal function during follow-up [99].

Increased excretion of urinary total protein is a classic marker of renal disease. Proteinuria and albuminuria are useful markers of vasculopathy and are known to be independent predictors of cardiovascular morbidity and mortality in patients with other vasculopathic diseases, such as diabetes and hypertension [100, 101]. Vascular kidney damage can be detected at an early stage by increased permeability of proteins passing the glomerular filtration barrier.

Seiberlich et al. [102] analyzed urine albumin, urine total protein and urine electrophoresis to assess protein excretion in 80 SSc patients and 18 healthy age- and gender-matched controls, all with normal GFRs. Increased total protein excretion was detected in 17.5% of SSc patients, and albuminuria was identified in 25%. Albuminuria correlated with disease duration >4 years and elevation of systolic blood pressure, suggesting it may be reflective of chronic vascular injury [102].

Proteinuria >1 g/day in SSc is uncommon and suggests an underlying glomerular disorder. In the context of serological features of lupus, significant proteinuria should be verified by renal biopsy [55].

In regard to SSc, epidemiological studies have identified proteinuria as a risk factor for increased mortality [102-104]. In patients with SSc and proteinuria, initiation of ACE-I therapy resulted in a significant decrease in urine protein excretion [105].

Renal involvement in patients with SSc may have a variable clinicopathological course (Table 4). The spectrum of kidney involvement includes the following: asymptomatic reduction of the GFR, ANCA-associated vasculitis, an isolated reduced GFR in scleroderma, aPL-associated nephropathy, high intrarenal arterial stiffness and proteinuria. SRC is the most specific and life-threatening renal presentation of SSc; however, in recent years, declining frequencies have been observed.

Table 4.

Renal manifestations of SSc

Renal manifestations of SSc
Renal manifestations of SSc

In patients with established SRC, it is mandatory to control blood pressure early with increasing doses of ACE-I, along with other antihypertensive drugs if necessary. The lack of specific diagnostic criteria for SRC is an ongoing problem. A consensus of experts evaluated a broad list of potential diagnostic items in order to identify the key aspects of SRC.

Autoimmune serology – anti-RNAP III antibodies and anti-Topo I – can be used to identify patients with a higher risk of SRC. sTIM3 was also found to be frequently elevated in patients with a history of SRC. NT-proBNP has been proposed as a potentially useful biomarker in risk stratification of renal outcome in SRC, identifying patients in whom renal replacement therapy is more likely to be required. Recently, adipokines have attracted much attention as potential new biomarkers due to their contribution to the various pathological processes in SSc. There is a strong association between renal involvement and patients’ outcomes in SSc. Consequently, it seems mandatory to find markers that may be used to identify patients with an especially high risk of SRC. The key points are summarized in Table 5.

Table 5.

Summary of key points

Summary of key points
Summary of key points

The authors have no conflicts of interest to declare.

There are no funding sources for this review.

All authors conceived the manuscript and collected the literature; M.C., M.S. and L.R. drafted the manuscript; J.M. and J.M.R. provided a critical review of the nephrology part; all authors edited and approved the final version of the manuscript.

1.
Asano
Y
.
Systemic sclerosis
.
J Dermatol
.
2018
Feb
;
45
(
2
):
128
38
.
[PubMed]
0385-2407
2.
Orlandi
,
M.
, et al.
, One year in review 2018: systemic sclerosis. Clin Exp Rheumatol,
2018
. 36 Suppl 113(4): p. 3-23.
3.
Shanmugam
,
V.K.
and
V.D.
Steen
, Renal Manifestations in Scleroderma: Evidence for Subclinical Renal Disease as a Marker of Vasculopathy. International Journal of Rheumatology, 2010.
2010
.
4.
Shanavas
N
,
Das
A
.
Profile of systemic sclerosis and associated renal involvement
.
Archives of Medicine and Health Sciences
.
2015
;
3
(
2
):
209
14
.
5.
Minier
T
,
Guiducci
S
,
Bellando-Randone
S
,
Bruni
C
,
Lepri
G
,
Czirják
L
, et al.;
EUSTAR co-workers
;
EUSTAR co-workers
.
Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis
.
Ann Rheum Dis
.
2014
Dec
;
73
(
12
):
2087
93
.
[PubMed]
0003-4967
6.
Trostle
DC
,
Bedetti
CD
,
Steen
VD
,
Al-Sabbagh
MR
,
Zee
B
,
Medsger
TA
 Jr
.
Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study
.
Arthritis Rheum
.
1988
Mar
;
31
(
3
):
393
400
.
[PubMed]
0004-3591
7.
Cannon
J
. P., et al., The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Vol. 53.
1974
. 1-46.
8.
Li
X
,
Qian
YQ
,
Liu
N
,
Mu
R
,
Zuo
Y
,
Wang
GC
, et al.
Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study
.
Clin Rheumatol
.
2018
Nov
;
37
(
11
):
3051
6
.
[PubMed]
0770-3198
9.
Hao
Y
,
Hudson
M
,
Baron
M
,
Carreira
P
,
Stevens
W
,
Rabusa
C
, et al.;
Canadian Scleroderma Research Group
;
Australian Scleroderma Interest Group
.
Early Mortality in a Multinational Systemic Sclerosis Inception Cohort
.
Arthritis Rheumatol
.
2017
May
;
69
(
5
):
1067
77
.
[PubMed]
2326-5191
10.
Penn
H
,
Howie
AJ
,
Kingdon
EJ
,
Bunn
CC
,
Stratton
RJ
,
Black
CM
, et al.
Scleroderma renal crisis: patient characteristics and long-term outcomes
.
QJM
.
2007
Aug
;
100
(
8
):
485
94
.
[PubMed]
1460-2725
11.
Teixeira
L
,
Mouthon
L
,
Mahr
A
,
Berezné
A
,
Agard
C
,
Mehrenberger
M
, et al.;
Group Français de Recherche sur le Sclérodermie (GFRS)
.
Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients
.
Ann Rheum Dis
.
2008
Jan
;
67
(
1
):
110
6
.
[PubMed]
0003-4967
12.
Steen
VD
,
Medsger
TA
.
Changes in causes of death in systemic sclerosis, 1972-2002
.
Ann Rheum Dis
.
2007
Jul
;
66
(
7
):
940
4
.
[PubMed]
0003-4967
13.
Hoffmann-Vold
AM
,
Distler
O
,
Murray
B
,
Kowal-Bielecka
O
,
Khanna
D
,
Allanore
Y
;
EUSTAR and SCTC collaborators
.
Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features
.
RMD Open
.
2019
Mar
;
5
(
1
):
e000826
.
[PubMed]
2399-4983
14.
Denton
CP
,
Khanna
D
.
Systemic sclerosis
.
Lancet
.
2017
Oct
;
390
(
10103
):
1685
99
.
[PubMed]
0140-6736
15.
Turk
M
,
Pope
JE
.
The Frequency of Scleroderma Renal Crisis over Time: A Metaanalysis
.
J Rheumatol
.
2016
Jul
;
43
(
7
):
1350
5
.
[PubMed]
0315-162X
16.
Maurer
B
,
Graf
N
,
Michel
BA
,
Müller-Ladner
U
,
Czirják
L
,
Denton
CP
, et al.;
EUSTAR co-authors
.
Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database
.
Ann Rheum Dis
.
2015
Jun
;
74
(
6
):
1124
31
.
[PubMed]
0003-4967
17.
Ishizu
A
,
Fukaya
S
,
Tomaru
U
,
Katsumata
K
,
Suzuki
A
,
Umemoto
Y
, et al.
Acute Renal Failure due to Thrombotic Microangiopathy in Patient with Scleroderma: Autopsy Case Report
.
Ann Vasc Dis
.
2012
;
5
(
4
):
458
61
.
[PubMed]
1881-641X
18.
Mihai
C
,
Tervaert
JW
.
Anti-endothelial cell antibodies in systemic sclerosis
.
Ann Rheum Dis
.
2010
Feb
;
69
(
2
):
319
24
.
[PubMed]
0003-4967
19.
Steen
VD
,
Syzd
A
,
Johnson
JP
,
Greenberg
A
,
Medsger
TA
 Jr
.
Kidney disease other than renal crisis in patients with diffuse scleroderma
.
J Rheumatol
.
2005
Apr
;
32
(
4
):
649
55
.
[PubMed]
0315-162X
20.
Fonseca
C
,
Renzoni
E
,
Sestini
P
,
Pantelidis
P
,
Lagan
A
,
Bunn
C
, et al.
Endothelin axis polymorphisms in patients with scleroderma
.
Arthritis Rheum
.
2006
Sep
;
54
(
9
):
3034
42
.
[PubMed]
0004-3591
21.
Herrick
AL
.
Vascular function in systemic sclerosis
.
Curr Opin Rheumatol
.
2000
Nov
;
12
(
6
):
527
33
.
[PubMed]
1040-8711
22.
Kobayashi
H
,
Nishimaki
T
,
Kaise
S
,
Suzuki
T
,
Watanabe
K
,
Kasukawa
R
, et al.
Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis
.
Clin Rheumatol
.
1999
;
18
(
5
):
425
7
.
[PubMed]
0770-3198
23.
Sakkas
LI
.
New developments in the pathogenesis of systemic sclerosis
.
Autoimmunity
.
2005
Mar
;
38
(
2
):
113
6
.
[PubMed]
0891-6934
24.
Chizzolini
C
.
Update on pathophysiology of scleroderma with special reference to immunoinflammatory events
.
Ann Med
.
2007
;
39
(
1
):
42
53
.
[PubMed]
0785-3890
25.
Sato
S
,
Fujimoto
M
,
Hasegawa
M
,
Takehara
K
,
Tedder
TF
.
Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis
.
Mol Immunol
.
2004
Nov
;
41
(
12
):
1123
33
.
[PubMed]
0161-5890
26.
Sakkas
LI
,
Chikanza
IC
,
Platsoucas
CD
.
Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis
.
Nat Clin Pract Rheumatol
.
2006
Dec
;
2
(
12
):
679
85
.
[PubMed]
1745-8382
27.
Chang
M
,
Wang
RJ
,
Yangco
DT
,
Sharp
GC
,
Komatireddy
GR
,
Hoffman
RW
.
Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay
.
Clin Immunol Immunopathol
.
1998
Oct
;
89
(
1
):
71
8
.
[PubMed]
0090-1229
28.
Santiago
M
,
Baron
M
,
Hudson
M
,
Burlingame
RW
,
Fritzler
MJ
.
Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA
.
J Rheumatol
.
2007
Jul
;
34
(
7
):
1528
34
.
[PubMed]
0315-162X
29.
Batal
I
,
Domsic
RT
,
Shafer
A
,
Medsger
TA
 Jr
,
Kiss
LP
,
Randhawa
P
, et al.
Renal biopsy findings predicting outcome in scleroderma renal crisis
.
Hum Pathol
.
2009
Mar
;
40
(
3
):
332
40
.
[PubMed]
0046-8177
30.
Agarwal
SK
.
The genetics of systemic sclerosis
.
Discov Med
.
2010
Aug
;
10
(
51
):
134
43
.
[PubMed]
1944-7930
31.
Yanaba
K
,
Asano
Y
,
Tada
Y
,
Sugaya
M
,
Kadono
T
,
Hamaguchi
Y
, et al.
Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis
.
Clin Rheumatol
.
2012
May
;
31
(
5
):
835
9
.
[PubMed]
0770-3198
32.
Steen
VD
,
Medsger
TA
 Jr
.
Long-term outcomes of scleroderma renal crisis
.
Ann Intern Med
.
2000
Oct
;
133
(
8
):
600
3
.
[PubMed]
0003-4819
33.
Pasha
F
,
Abazari
S
,
Bikarannejad
P
,
Zabolian
A
.
Systemic Sclerosis with Focus on Scleroderma Renal Crisis
.
Iran J Kidney Dis
.
2019
May
;
13
(
3
):
207
10
.
[PubMed]
1735-8604
34.
Steen
VD
.
Scleroderma renal crisis
.
Rheum Dis Clin North Am
.
2003
May
;
29
(
2
):
315
33
.
[PubMed]
0889-857X
35.
Denton
CP
,
Lapadula
G
,
Mouthon
L
,
Müller-Ladner
U
.
Renal complications and scleroderma renal crisis
.
Rheumatology (Oxford)
.
2009
Jun
;
48
Suppl 3
:
iii32
5
.
[PubMed]
1462-0324
36.
Denton
CP
,
Bickerstaff
MC
,
Shiwen
X
,
Carulli
MT
,
Haskard
DO
,
Dubois
RM
, et al.
Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis
.
Br J Rheumatol
.
1995
Nov
;
34
(
11
):
1048
54
.
[PubMed]
0263-7103
37.
Butler
EA
,
Baron
M
,
Fogo
AB
,
Frech
T
,
Ghossein
C
,
Hachulla
E
, et al.;
Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group
.
Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology
.
Arthritis Rheumatol
.
2019
Jun
;
71
(
6
):
964
71
.
[PubMed]
2326-5191
38.
Hoa
S
,
Stern
EP
,
Denton
CP
,
Hudson
M
,
Baron
M
,
Frech
T
, et al.;
Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group Investigators of the Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group
.
Towards developing criteria for scleroderma renal crisis: A scoping review
.
Autoimmun Rev
.
2017
Apr
;
16
(
4
):
407
15
.
[PubMed]
1568-9972
39.
Mouthon
L
,
Bussone
G
,
Berezné
A
,
Noël
LH
,
Guillevin
L
.
Scleroderma renal crisis
.
J Rheumatol
.
2014
Jun
;
41
(
6
):
1040
8
.
[PubMed]
0315-162X
40.
Cheta
J
,
Binder
M
,
Kowalewska
J
,
Magoon
S
.
ANCA-Associated Vasculitis Co-Occurrence With Systemic Sclerosis: A Case Report of a Rare Diagnostic Dilemma
.
J Investig Med High Impact Case Rep
.
2018
Jun
;
6
:
2324709618785188
.
[PubMed]
2324-7096
41.
Lusco
MA
,
Najafian
B
,
Alpers
CE
,
Fogo
AB
.
AJKD Atlas of Renal Pathology: systemic Sclerosis
.
Am J Kidney Dis
.
2016
Apr
;
67
(
4
):
e19
20
.
[PubMed]
0272-6386
42.
Steen
VD
,
Medsger
TA
 Jr
,
Osial
TA
 Jr
,
Ziegler
GL
,
Shapiro
AP
,
Rodnan
GP
.
Factors predicting development of renal involvement in progressive systemic sclerosis
.
Am J Med
.
1984
May
;
76
(
5
):
779
86
.
[PubMed]
0002-9343
43.
Moinzadeh
P
, et al.
Scleroderma renal crisis (SRC): risk factors for an increasingly rare organ complication
.
J Rheumatol
.
2019
.
[PubMed]
0315-162X
44.
Terras
S
,
Hartenstein
H
,
Höxtermann
S
,
Gambichler
T
,
Kreuter
A
.
RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis
.
Int J Dermatol
.
2016
Aug
;
55
(
8
):
882
5
.
[PubMed]
0011-9059
45.
Stochmal
A
, et al.
Antinuclear Antibodies in Systemic Sclerosis: an Update
.
Clin Rev Allergy Immunol
.
2019
.
[PubMed]
1080-0549
46.
Takada
D
,
Hoshino
J
,
Kikuchi
K
,
Yabuuchi
J
,
Kogure
Y
,
Ueno
T
, et al.
Anti-RNA polymerase III antibody-associated scleroderma renal crisis in a patient with limited cutaneous systemic sclerosis: A case report
.
Mod Rheumatol
.
2018
Mar
;
28
(
2
):
369
72
.
[PubMed]
1439-7595
47.
DeMarco
PJ
,
Weisman
MH
,
Seibold
JR
,
Furst
DE
,
Wong
WK
,
Hurwitz
EL
, et al.
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial
.
Arthritis Rheum
.
2002
Nov
;
46
(
11
):
2983
9
.
[PubMed]
0004-3591
48.
Shimizu
T
,
Iwamoto
N
,
Okamoto
M
,
Endo
Y
,
Tsuji
S
,
Takatani
A
, et al.
Scleroderma Renal Crisis Complicated with Thrombotic Microangiopathy Triggered by Influenza B Virus Infection
.
Intern Med
.
2019
Feb
;
58
(
3
):
441
5
.
[PubMed]
0918-2918
49.
Steen
VD
,
Medsger
TA
 Jr
.
Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis
.
Arthritis Rheum
.
1998
Sep
;
41
(
9
):
1613
9
.
[PubMed]
0004-3591
50.
Steen
VD
.
Kidney involvement in systemic sclerosis
.
Presse Med
.
2014
Oct
;
43
(
10 Pt 2
):
e305
14
.
[PubMed]
0755-4982
51.
Denton
CP
,
Sweny
P
,
Abdulla
A
,
Black
CM
.
Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases
.
Br J Rheumatol
.
1994
Jan
;
33
(
1
):
90
2
.
[PubMed]
0263-7103
52.
Zanatta
E
,
Polito
P
,
Favaro
M
,
Larosa
M
,
Marson
P
,
Cozzi
F
, et al.
Therapy of scleroderma renal crisis: state of the art
.
Autoimmun Rev
.
2018
Sep
;
17
(
9
):
882
9
.
[PubMed]
1568-9972
53.
Shanmugam
VK
,
Steen
VD
.
Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management
.
Curr Opin Rheumatol
.
2012
Nov
;
24
(
6
):
669
76
.
[PubMed]
1040-8711
54.
Nagaraja
V
.
Management of scleroderma renal crisis
.
Curr Opin Rheumatol
.
2019
May
;
31
(
3
):
223
30
.
[PubMed]
1040-8711
55.
Penn
H
,
Denton
CP
.
Diagnosis, management and prevention of scleroderma renal disease
.
Curr Opin Rheumatol
.
2008
Nov
;
20
(
6
):
692
6
.
[PubMed]
1040-8711
56.
Gordon
SM
,
Stitt
RS
,
Nee
R
,
Bailey
WT
,
Little
DJ
,
Knight
KR
, et al.
Risk Factors for Future Scleroderma Renal Crisis at Systemic Sclerosis Diagnosis
.
J Rheumatol
.
2019
Jan
;
46
(
1
):
85
92
.
[PubMed]
0315-162X
57.
Krasowska
,
D.
, et al.
, Systemic sclerosis – diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1: diagnosis and monitoring. Dermatology Review/Przegląd Dermatologiczny,
2017
. 104(5): p. 483-498.
58.
Pham
PT
,
Pham
PC
,
Danovitch
GM
,
Gritsch
HA
,
Singer
J
,
Wallace
WD
, et al.
Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature
.
Am J Transplant
.
2005
Oct
;
5
(
10
):
2565
9
.
[PubMed]
1600-6135
59.
Uriarte
MH
,
Larrarte
C
,
Rey
LB
.
Scleroderma Renal Crisis Debute with Thrombotic Microangiopathy: A Successful Case Treated with Eculizumab
.
Case Rep Nephrol
.
2018
Oct
;
2018
:
6051083
.
[PubMed]
2090-6641
60.
Devresse
A
,
Aydin
S
,
Le Quintrec
M
,
Demoulin
N
,
Stordeur
P
,
Lambert
C
, et al.
Complement activation and effect of eculizumab in scleroderma renal crisis
.
Medicine (Baltimore)
.
2016
Jul
;
95
(
30
):
e4459
.
[PubMed]
0025-7974
61.
Gibney
EM
,
Parikh
CR
,
Jani
A
,
Fischer
MJ
,
Collier
D
,
Wiseman
AC
.
Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity
.
Am J Transplant
.
2004
Dec
;
4
(
12
):
2027
31
.
[PubMed]
1600-6135
62.
Kronbichler
A
,
Mayer
G
.
Renal involvement in autoimmune connective tissue diseases
.
BMC Med
.
2013
Apr
;
11
(
1
):
95
.
[PubMed]
1741-7015
63.
Hruskova
Z
,
Pippias
M
,
Stel
VS
,
Abad-Díez
JM
,
Benítez Sánchez
M
,
Caskey
FJ
, et al.
Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry
.
Am J Kidney Dis
.
2019
Feb
;
73
(
2
):
184
93
.
[PubMed]
0272-6386
64.
Siva
B
,
McDonald
SP
,
Hawley
CM
,
Rosman
JB
,
Brown
FG
,
Wiggins
KJ
, et al.
End-stage kidney disease due to scleroderma—outcomes in 127 consecutive ANZDATA registry cases
.
Nephrol Dial Transplant
.
2011
Oct
;
26
(
10
):
3165
71
.
[PubMed]
0931-0509
65.
Steen
VD
,
Ziegler
GL
,
Rodnan
GP
,
Medsger
TA
 Jr
.
Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis
.
Arthritis Rheum
.
1984
Feb
;
27
(
2
):
125
31
.
[PubMed]
0004-3591
66.
Bunn
CC
,
Denton
CP
,
Shi-Wen
X
,
Knight
C
,
Black
CM
.
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis
.
Br J Rheumatol
.
1998
Jan
;
37
(
1
):
15
20
.
[PubMed]
0263-7103
67.
Okano
Y
,
Steen
VD
,
Medsger
TA
 Jr
.
Autoantibody reactive with RNA polymerase III in systemic sclerosis
.
Ann Intern Med
.
1993
Nov
;
119
(
10
):
1005
13
.
[PubMed]
0003-4819
68.
Codullo
V
,
Cavazzana
I
,
Bonino
C
,
Alpini
C
,
Cavagna
L
,
Cozzi
F
, et al.
Serologic profile and mortality rates of scleroderma renal crisis in Italy
.
J Rheumatol
.
2009
Jul
;
36
(
7
):
1464
9
.
[PubMed]
0315-162X
69.
Chiba
M
,
Yanaba
K
,
Hayashi
M
,
Yoshihara
Y
,
Nakagawa
H
.
Clinical significance of serum soluble T-cell immunoglobulin and mucin domain 3 levels in systemic sclerosis: association with disease severity
.
J Dermatol
.
2017
Feb
;
44
(
2
):
194
7
.
[PubMed]
0385-2407
70.
Chighizola
,
C.B.
, et al.
, N-terminal pro Brain Natriuretic Peptide as predictor of outcome in scleroderma renal crisis. Clin Exp Rheumatol,
2016
. 34 Suppl 100(5): p. 122-128.
71.
Zylla
S
,
Rettig
R
,
Völzke
H
,
Endlich
K
,
Nauck
M
,
Friedrich
N
.
Serum chemerin levels are inversely associated with renal function in a general population
.
Clin Endocrinol (Oxf)
.
2018
Jan
;
88
(
1
):
146
53
.
[PubMed]
0300-0664
72.
Żółkiewicz
J
,
Stochmal
A
,
Rudnicka
L
.
The role of adipokines in systemic sclerosis: a missing link?
Arch Dermatol Res
.
2019
May
;
311
(
4
):
251
63
.
[PubMed]
0340-3696
73.
Huang
S
,
Chen
L
,
Lu
L
,
Li
L
.
The apelin-APJ axis: A novel potential therapeutic target for organ fibrosis
.
Clin Chim Acta
.
2016
May
;
456
:
81
8
.
[PubMed]
0009-8981
74.
Sawicka
K
,
Krasowska
D
.
Adipokines in connective tissue diseases
.
Clin Exp Rheumatol
.
2016
Nov-Dec
;
34
(
6
):
1101
12
.
[PubMed]
0392-856X
75.
Helfrich
DJ
,
Banner
B
,
Steen
VD
,
Medsger
TA
 Jr
.
Normotensive renal failure in systemic sclerosis
.
Arthritis Rheum
.
1989
Sep
;
32
(
9
):
1128
34
.
[PubMed]
0004-3591
76.
Bashandy
HG
,
Javillo
JS
,
Gambert
SR
.
A case of early onset normotensive scleroderma renal crisis in a patient with diffuse cutaneous systemic sclerosis
.
South Med J
.
2006
Aug
;
99
(
8
):
870
2
.
[PubMed]
0038-4348
77.
Steen
VD
,
Mayes
MD
,
Merkel
PA
.
Assessment of kidney involvement
.
Clin Exp Rheumatol
.
2003
;
21
(
3
Suppl 29
):
S29
31
.
[PubMed]
0392-856X
78.
Montrief
T
,
Koyfman
A
,
Long
B
.
Scleroderma renal crisis: a review for emergency physicians
.
Intern Emerg Med
.
2019
Jun
;
14
(
4
):
561
70
.
[PubMed]
1828-0447
79.
Denton
CP
.
Renal manifestations of systemic sclerosis—clinical features and outcome assessment
.
Rheumatology (Oxford)
.
2008
Oct
;
47
Suppl 5
:
v54
6
.
[PubMed]
1462-0324
80.
Batal
I
,
Domsic
RT
,
Medsger
TA
,
Bastacky
S
.
Scleroderma renal crisis: a pathology perspective
.
Int J Rheumatol
.
2010
;
2010
:
543704
.
[PubMed]
1687-9260
81.
Akoglu
H
,
Atilgan
GK
,
Ozturk
R
,
Yenigun
EC
,
Gonul
II
,
Odabas
AR
.
A “silent” course of normotensive scleroderma renal crisis: case report and review of the literature
.
Rheumatol Int
.
2009
Aug
;
29
(
10
):
1223
9
.
[PubMed]
0172-8172
82.
Jennette
JC
,
Falk
RJ
,
Gasim
AH
.
Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis
.
Curr Opin Nephrol Hypertens
.
2011
May
;
20
(
3
):
263
70
.
[PubMed]
1062-4821
83.
Derrett-Smith
EC
,
Nihtyanova
SI
,
Harvey
J
,
Salama
AD
,
Denton
CP
.
Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors
.
Rheumatology (Oxford)
.
2013
Oct
;
52
(
10
):
1824
31
.
[PubMed]
1462-0324
84.
Arnaud
L
,
Huart
A
,
Plaisier
E
,
Francois
H
,
Mougenot
B
,
Tiev
K
, et al.
ANCA-related crescentic glomerulonephritis in systemic sclerosis: revisiting the “normotensive scleroderma renal crisis”
.
Clin Nephrol
.
2007
Sep
;
68
(
3
):
165
70
.
[PubMed]
0301-0430
85.
Kao
,
L.
and
C.
Weyand
,
Vasculitis in Systemic Sclerosis.
International Journal of Rheumatology, 2010.
2010
.
86.
Arad
U
,
Balbir-Gurman
A
,
Doenyas-Barak
K
,
Amit-Vazina
M
,
Caspi
D
,
Elkayam
O
.
Anti-neutrophil antibody associated vasculitis in systemic sclerosis
.
Semin Arthritis Rheum
.
2011
Oct
;
41
(
2
):
223
9
.
[PubMed]
0049-0172
87.
Ostojic
P
,
Stojanovski
N
.
Arterial hypertension treated with angiotensin converting enzyme inhibitors and glucocorticoids are independent risk factors associated with decreased glomerular filtration rate in systemic sclerosis
.
Rheumatol Int
.
2017
Mar
;
37
(
3
):
363
8
.
[PubMed]
0172-8172
88.
Campo
A
,
Mathai
SC
,
Le Pavec
J
,
Zaiman
AL
,
Hummers
LK
,
Boyce
D
, et al.
Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension
.
Am J Respir Crit Care Med
.
2010
Jul
;
182
(
2
):
252
60
.
[PubMed]
1073-449X
89.
Cervera
R
,
Piette
JC
,
Font
J
,
Khamashta
MA
,
Shoenfeld
Y
,
Camps
MT
, et al.;
Euro-Phospholipid Project Group
.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
.
Arthritis Rheum
.
2002
Apr
;
46
(
4
):
1019
27
.
[PubMed]
0004-3591
90.
Joseph
RE
,
Radhakrishnan
J
,
Appel
GB
.
Antiphospholipid antibody syndrome and renal disease
.
Curr Opin Nephrol Hypertens
.
2001
Mar
;
10
(
2
):
175
81
.
[PubMed]
1062-4821
91.
Assous
N
,
Allanore
Y
,
Batteux
F
,
Meune
C
,
Toulon
P
,
Weill
B
, et al.
Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury
.
Clin Exp Rheumatol
.
2005
Mar-Apr
;
23
(
2
):
199
204
.
[PubMed]
0392-856X
92.
Picillo
U
,
Migliaresi
S
,
Marcialis
MR
,
Ferruzzi
AM
,
Tirri
G
.
Clinical significance of anticardiolipin antibodies in patients with systemic sclerosis
.
Autoimmunity
.
1995
;
20
(
1
):
1
7
.
[PubMed]
0891-6934
93.
Wielosz
E
,
Majdan
M
,
Zychowska
I
,
Jeleniewicz
R
.
Coexistence of five autoimmune diseases: diagnostic and therapeutic difficulties
.
Rheumatol Int
.
2008
Jul
;
28
(
9
):
919
23
.
[PubMed]
0172-8172
94.
Malia
RG
,
Greaves
M
,
Rowlands
LM
,
Lawrence
AC
,
Hume
A
,
Rowell
NR
, et al.
Anticardiolipin antibodies in systemic sclerosis: immunological and clinical associations
.
Clin Exp Immunol
.
1988
Sep
;
73
(
3
):
456
60
.
[PubMed]
0009-9104
95.
Wielosz
E
,
Dryglewska
M
,
Majdan
M
.
Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis
.
Clin Rheumatol
.
2009
Aug
;
28
(
8
):
955
9
.
[PubMed]
0770-3198
96.
Rosato
E
,
Gigante
A
,
Barbano
B
,
Cianci
R
,
Molinaro
I
,
Rossi
C
, et al.
Intrarenal hemodynamic parameters correlate with glomerular filtration rate and digital microvascular damage in patients with systemic sclerosis
.
Semin Arthritis Rheum
.
2012
Jun
;
41
(
6
):
815
21
.
[PubMed]
0049-0172
97.
Rosato
E
,
Barbano
B
,
Gigante
A
,
Molinaro
I
,
Quarta
S
,
Pisarri
S
, et al.
Increased intrarenal arterial stiffness may predict the occurrence of new digital ulcers in systemic sclerosis
.
Arthritis Care Res (Hoboken)
.
2014
Sep
;
66
(
9
):
1380
5
.
[PubMed]
2151-464X
98.
Rosato
E
,
Gigante
A
,
Barbano
B
,
Molinaro
I
,
Cianci
R
,
Salsano
F
.
Doppler indices of intrarenal arterial stiffness are useful in monitoring scleroderma renal crisis
.
Scand J Rheumatol
.
2013
;
42
(
1
):
80
1
.
[PubMed]
0300-9742
99.
Rosato
E
,
Gigante
A
,
Barbano
B
,
Gasperini
ML
,
Cianci
R
,
Muscaritoli
M
.
Prognostic Factors of Renal Involvement in Systemic Sclerosis
.
Kidney Blood Press Res
.
2018
;
43
(
3
):
682
9
.
[PubMed]
1420-4096
100.
Go
AS
,
Chertow
GM
,
Fan
D
,
McCulloch
CE
,
Hsu
CY
.
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
.
N Engl J Med
.
2004
Sep
;
351
(
13
):
1296
305
.
[PubMed]
0028-4793
101.
Klausen
K
,
Borch-Johnsen
K
,
Feldt-Rasmussen
B
,
Jensen
G
,
Clausen
P
,
Scharling
H
, et al.
Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes
.
Circulation
.
2004
Jul
;
110
(
1
):
32
5
.
[PubMed]
0009-7322
102.
Seiberlich
B
,
Hunzelmann
N
,
Krieg
T
,
Weber
M
,
Schulze-Lohoff
E
.
Intermediate molecular weight proteinuria and albuminuria identify scleroderma patients with increased morbidity
.
Clin Nephrol
.
2008
Aug
;
70
(
2
):
110
7
.
[PubMed]
0301-0430
103.
Joven
BE
,
Almodovar
R
,
Carmona
L
,
Carreira
PE
.
Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital
.
Semin Arthritis Rheum
.
2010
Feb
;
39
(
4
):
285
93
.
[PubMed]
0049-0172
104.
Tyndall
AJ
,
Bannert
B
,
Vonk
M
,
Airò
P
,
Cozzi
F
,
Carreira
PE
, et al.
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database
.
Ann Rheum Dis
.
2010
Oct
;
69
(
10
):
1809
15
.
[PubMed]
0003-4967
105.
Schuster
J
,
Moinzadeh
P
,
Kurschat
C
,
Benzing
T
,
Krieg
T
,
Weber
M
, et al.
Proteinuria in systemic sclerosis: reversal by ACE inhibition
.
Rheumatol Int
.
2013
Sep
;
33
(
9
):
2225
30
.
[PubMed]
0172-8172
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.